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and OpportunitiesScreening for abdominal aortic aneurysm (AAA) has been
shown to be effective at reducing AAA-related mortality and
is cost-effective.1 There are, however, signiﬁcant variations
in AAA screening protocols between healthcare systems2
and numerous challenges to be overcome. Further
evidence of cost- and clinical effectiveness is likely to be
required before there is widespread international adoption
of AAA screening.
ECONOMICS
One of the key arguments against AAA screening is the
declining prevalence of disease, potentially reducing any
economic beneﬁt. Cost-effectiveness has, however, been
demonstrated (at current prevalence rates) by the English
Aneurysm screening programme.3 The Viborg screening
trial4 has shown that a once-only screening strategy is
highly cost-effective (at current AAA prevalence rates) and
would remain so at a prevalence of 1.6%, which is half that
observed in the original Viborg study. In Sweden, screening
is cost-effective at current AAA prevalence rates5 and will
remain so even for an AAA prevalence of 0.5%, unless there
is an increase in the rate at which aneurysms are detected
prior to screening.
AAA screening is intrinsically linked to ongoing disease
surveillance. Long-term modelling suggests that cost-
effectiveness could be improved by lengthening surveil-
lance intervals for smaller AAAs, but potential cost savings
are relatively limited.6 Other factors related to the
cost-effectiveness of AAA screening include the degree to
which lives are lengthened by detecting an AAA and the
quality of this improved lifespan. Both the improvement in
length of life afforded by AAA screening and the quality of
this extended life were assessed in the UK by the MASS
trial.1 While the majority of screened individuals had no
signiﬁcant change in quality of life, there were small
subgroups of vulnerable individuals for whom screening had
a negative effect on quality of life.7,8 Contemporary data
regarding the outcomes of screening for AAA, including
unbiased assessments of the effect of screening on quality,
as well as length, of life are required and should be the
focus of future research. In particular, it may be necessary
to evaluate whether providing additional support (both
before and after screening), in a comprehensive or targeted
fashion, is worthwhile.1078-5884/$ e see front matter  2014 European Society for Vascular
Surgery. Published by Elsevier Ltd. All rights reserved.
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A speciﬁc subgroup that has attracted considerable atten-
tion includes patients with an internal aortic diameter of
25e29 mm, when the external diameter may already have
reached the 30-mm threshold. These patients are not usu-
ally considered to have an AAA, but data suggest they have
a signiﬁcant risk (50%) of developing an AAA within 5 years
of the initial scan.9 More importantly, there is no interna-
tional consensus on the preferred method for ultrasound
measurement of infra-renal aortic diameter and the
methods used have often been poorly documented in the
various randomized controlled trials. Three methods are in
current use: inner-to-inner,10 outer-to-outer,11 and
leading-edge-to-leading-edge (outer anterior wall to inner
posterior wall).12 A recent publication comparing the three
methods showed the lowest variability with the leading-
edge-to-leading-edge method, which is routine in cardiac
ultrasound measurements.13 One consequence of changing
from outer-to-outer to inner-to-inner methodology, is that
this could result in some patients who would previously
have been diagnosed as having an AAA now being diag-
nosed as “normal”, that is they would fall into the sub-
aneurysmal aortic dilatation category. Whether these pa-
tients would require follow-up remains unknown. The
impact of measurement methodology on outcomes from
screening and the possible beneﬁt of re-screening these
types of patient also remain unknown.9
TARGET POPULATIONS
The majority of screening programmes recommend a single
ultrasound scan for males aged 65 years, irrespective of
medical history or risk factors such as smoking. The
exception is the US Veterans’ Administration (USVA)
screening programme, where only men with a history of
smoking are invited for screening. Currently, there is no
clinical trial evidence regarding the efﬁcacy of screening
targeted high-risk male sub-groups over the age of 65 years.
The incidence of AAA in the USVA programme, where only
previous or current smokers are offered screening, is
>7%.14 This compares with 1.8% for the NHS AAA Screening
Programme and 1.7% in the Swedish AAA screening
program. The USVA programme screens an older age group,
however, which makes direct comparison difﬁcult. It should
also be noted that these prevalence rates refer to screen-
detected AAA in asymptomatic patients, as patients with
known AAA disease are usually excluded from screening. In
114 Editorialaddition, disease prevalence rates in populations that would
be excluded by such targeted programmes have not been
sufﬁciently investigated and reduced life expectancy among
smokers may also reduce any potential gains from
screening.
Screening women for AAA remains controversial. Owing
to the lower prevalence of AAA in women, screening has
always been considered ineffective and there is no clinical
trial evidence to support screening in women. However,
given that the prevalence of AAA in female smokers is
around 2%,15 and that evidence from health economic
models of male AAA screening demonstrated cost effec-
tiveness at much lower prevalence rates, it would seem
intuitive that targeting female smokers might be cost-
effective. However, it is unclear whether detecting AAA in
women would result in an improvement in the length and
quality of life. This is because women tend to rupture their
AAA earlier in the disease process and have poorer out-
comes after AAA repair.16 To what extent these factors
would reduce the beneﬁt of early detection remains
unknown. Any studies of the effectiveness of screening
women for AAA would need to address this area of
uncertainty, either directly, or through statistical modelling.
In common with other screening programmes, data
suggest that males who are invited for AAA screening and
who do not attend may be at a higher risk of disease. In the
city and suburban areas of Malmö (Sweden), compliance
with screening varied between 64% and 89%.17 In areas
with low socioeconomic status, attendance rates were
lower, whereas AAA prevalence was higher. In another
Swedish study from the greater Stockholm area, several
different registries with socio-economic data were cross-
matched with the screening database.18 The most impor-
tant reasons for non-attendance were: recent immigration
(within 5 years), low income, being single or divorced, low
level of education, and long travel distances to the
screening centre. Targeting non-attenders for more
re-invitation may improve the effectiveness of AAA
screening, but requires assessment. However there also
is evidence that the incidence of AAA varies with
ethnicity19e23 and it may not be appropriate to target all
immigrant groups.
CARDIOVASCULAR RISK MANAGEMENT
One criticism of screening is that whilst it reduces aneurysm
related mortality, there is only a limited effect on overall
mortality. One of the main causes of death in populations
screened for AAA is cardiovascular disease and it is known
that aortic diameter is a predictor of cardiovascular mor-
tality.24 People with sub-aneurysmal aortic dilatation or
AAA are at higher risk of cardiovascular death than those
with normal infrarenal aortic diameter.25 It should also be
noted that the relationship between aortic diameter and
cardiovascular mortality is not linear and individuals with
both small and large aortic diameters are at higher risk of
cardiovascular mortality and morbidity.26 The increased risk
in patients with AAA is partly due to common risk factorsfor both AAA and other cardiovascular traits. There is some
evidence to suggest that having an AAA places an individual
at a higher risk of developing cardiovascular disease, irre-
spective of the presence or absence of traditional risk fac-
tors such as smoking and high blood pressure.27
The provision of secondary prevention between
screening programmes varies. In Sweden, patients with a
screen-detected AAA do not routinely receive additional
secondary preventative measures (other than smoking
cessation advice), unless they have clinical evidence of pre-
existing atherosclerosis. In the NHS AAA screening
programme, family doctors are advised to prescribe an
antiplatelet agent and a statin, together with smoking
cessation advice as appropriate. The beneﬁts and risks of
either management strategy have not been established.
CONCLUSIONS
The main challenge for proponents of AAA screening is the
demonstration of cost-effectiveness. AAA screening also
presents an opportunity to improve the general and, in
particular, cardiovascular health of individuals being
screened. Research and audit are evaluating and improving
evidence for the economics of AAA screening and have
demonstrated the true health value of AAA screening and
surveillance, with access to AAA screening for all high-risk
patient groups. Areas of potential quality improvement
include: (a) increasing compliance in populations with low
socio-economic status and a higher risk of AAA; and (b)
adding beneﬁt to AAA screening by determining if second-
ary cardiovascular prevention in high-risk groups based on
infrarenal aortic diameter measurement confers a reduction
in cardiovascular mortality.
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